Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: A nested case-control study

American Journal of Surgical Pathology

Volumn 29, Issue 1, 2005, Pages 105-108

  McLaren, Bernadette K ^a   Gobbi, Helenice ^b   Schuyler, Peggy A ^a   Olson, Sandra J ^a   Parl, Fritz F ^a   Dupont, William D ^a   Page, David L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Breast cancer; Enlarged lobular units with columnar alteration; Estrogen receptor

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; RISK ASSESSMENT;

ADENOCARCINOMA; BIOPSY; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; PRECANCEROUS CONDITIONS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TENNESSEE;

EID: 11144331380     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000146013.76881.d9     Document Type: Article

References (26)

1. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8: 47-61.
2. Anderson TJ, Battersby S, King RJ, et al. Oral contraceptive use influences resting breast proliferation. Hum Pathol. 1989;20:1139-1144.
3. Anderson TJ, Ferguson DJ, Raab GM. Cell turnover in the 'resting' human breast influence of parity, contraceptive pill, age and laterality. Br J Cancer. 1982;46:376-382.
4. Bonser G, Dossett J, Jull J. Human and Experimental Breast Cancer. London: Pitman Medical, 1961.
5. Byrne C, Webb PM, Jacobs TW, et al. Alcohol consumption and incidence of benign breast disease. Cancer Epidemiol Biomarkers Prev. 2002;11: 1369-1374.
6. Clarke RB, Howell A, Potten CS, et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997;57:4987-4991.
7. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol. 1987;125:769-779.
8. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.
9. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993; 71:1258-1265.
10. Erenburg I, Schachter B, Mira y Lopez R, et al. Loss of an estrogen receptor isoform (ER alpha delta 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol Endocrinol. 1997;11:2004-2015.
11. Ferguson DJ, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the 'resting' human breast. Br J Cancer. 1981;44:177-181.
12. Foote FW and Stewart FW. Comparative studies of cancerous versus noncancerous breasts. Ann Surg. 1945;121:197-222.
13. Fraser JL, Raza S, Chomy K, et al. Columnar alteration with prominent apical snouts and secretions: a spectrum of changes frequently present in breast biopsies performed for microcalcifications. Am J Surg Pathol. 1998;22:1521-1527.
14. Going JJ, Anderson TJ, Battersby S, et al. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol. 1988;130:193-204.
15. Hulley SB, Grady D. The WHI estrogen-alone trial: do things look any better? JAMA. 2004;291:1769-1771.
16. Iqbal M, Davies MP, Shoker BS, et al. Subgroups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells. J Pathol. 2001;193:333-338.
17. London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941-944.
18. Lu M, Miller KD, Gokmen-Polar Y, et al. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 2003;63:3425-3429.
19. Oyama T, Iijima K, Takei H, et al. Atypical cystic lobule of the breast: an early stage of low-grade ductal carcinoma in-situ. Breast Cancer. 2000; 7:326-331.
20. Page D, Anderson T. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987:362.
21. Page DL, Dupont WD, Rogers LW. Breast cancer risk of lobular-based hyperplasia after biopsy: 'ductal' pattern lesions. Cancer Detect Prev. 1986;9:441-448.
22. Parl F. Estrogens, Estrogen Receptor, and Breast Cancer. Amsterdam: IOS Press, 2000.
23. Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61:2537-2541.
24. Shaaban AM, Sloane JP, West CR, et al. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol. 2002;160:597-604.
25. Shaaban AM, Sloane JP, West CR, et al. Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study. Am J Surg Pathol. 2002;26:421-430.
26. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975;55:231-273.